Terns Historical Balance Sheet

TERN Stock

USD 5.71 0.11 1.96%

Trend analysis of Terns Pharmaceuticals balance sheet accounts such as Other Liabilities of 806.7 K, Net Tangible Assets of 334.4 M, Property Plant And Equipment Net of 1.2 M or Accounts Payable of 1.8 M provides information on Terns Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Terns Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Terns Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Terns Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Terns Pharmaceuticals is a good buy for the upcoming year.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.

About Terns Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Terns Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Terns Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Terns Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Terns currently owns. An asset can also be divided into two categories, current and non-current.

Terns Pharmaceuticals Balance Sheet Chart

At this time, Terns Pharmaceuticals' Net Invested Capital is very stable compared to the past year. As of the 22nd of November 2024, Property Plant Equipment is likely to grow to about 924 K, while Total Assets are likely to drop about 170.3 M.

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity Non Current Liabilities Other

Add Fundamental

Total Assets

Total assets refers to the total amount of Terns Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Terns Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Terns Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Terns Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most accounts from Terns Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Terns Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.At this time, Terns Pharmaceuticals' Net Invested Capital is very stable compared to the past year. As of the 22nd of November 2024, Property Plant Equipment is likely to grow to about 924 K, while Total Assets are likely to drop about 170.3 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	3.9M	4.4M	7.0M	5.1M
Total Assets	168.1M	287.0M	268.5M	170.3M

Other Current Liab Total Assets

Terns Pharmaceuticals balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Capital Stock	Net Working Capital
Total Assets		0.58	0.38	1.0	0.75	0.9	0.69	-0.57	-0.82	0.71	0.56	0.47	-0.86	-0.87	1.0	0.76	0.86	-0.76	0.71	0.89	-0.72	0.92	0.88	1.0	-0.78	1.0
Other Current Liab	0.58		0.94	0.56	0.91	0.51	0.81	0.09	-0.83	0.67	-0.02	0.74	-0.51	-0.54	0.53	0.65	0.65	-0.89	0.97	0.66	-0.1	0.49	0.76	0.57	-0.25	0.51
Total Current Liabilities	0.38	0.94		0.35	0.75	0.27	0.7	0.09	-0.63	0.39	0.01	0.65	-0.43	-0.44	0.33	0.41	0.41	-0.81	0.88	0.44	0.14	0.26	0.57	0.38	0.04	0.3
Total Stockholder Equity	1.0	0.56	0.35		0.74	0.9	0.69	-0.56	-0.81	0.71	0.56	0.46	-0.86	-0.87	1.0	0.75	0.86	-0.75	0.7	0.89	-0.74	0.93	0.88	1.0	-0.79	1.0
Other Liab	0.75	0.91	0.75	0.74		0.71	0.93	0.02	-0.92	0.86	0.01	0.83	-0.58	-0.61	0.73	0.69	0.81	-0.92	0.92	0.82	-0.44	0.71	0.95	0.75	-0.56	0.71
Net Tangible Assets	0.9	0.51	0.27	0.9	0.71		0.63	-0.39	-0.89	0.8	0.35	0.46	-0.81	-0.84	0.9	0.74	0.98	-0.73	0.63	0.98	-0.82	0.99	0.84	0.9	-0.92	0.9
Property Plant And Equipment Net	0.69	0.81	0.7	0.69	0.93	0.63		-0.11	-0.83	0.7	0.15	0.95	-0.51	-0.52	0.67	0.47	0.72	-0.86	0.78	0.76	-0.4	0.66	0.92	0.69	-0.5	0.65
Net Debt	-0.57	0.09	0.09	-0.56	0.02	-0.39	-0.11		0.12	0.15	-0.99	0.09	0.59	0.56	-0.58	-0.17	-0.24	0.13	-0.03	-0.3	0.34	-0.44	-0.21	-0.57	0.27	-0.59
Retained Earnings	-0.82	-0.83	-0.63	-0.81	-0.92	-0.89	-0.83	0.12		-0.88	-0.12	-0.72	0.7	0.75	-0.8	-0.79	-0.96	0.9	-0.87	-0.96	0.55	-0.87	-0.92	-0.81	0.72	-0.79
Accounts Payable	0.71	0.67	0.39	0.71	0.86	0.8	0.7	0.15	-0.88		-0.18	0.62	-0.5	-0.54	0.71	0.77	0.87	-0.73	0.73	0.85	-0.65	0.78	0.86	0.71	-0.8	0.7
Cash	0.56	-0.02	0.01	0.56	0.01	0.35	0.15	-0.99	-0.12	-0.18		-0.06	-0.59	-0.56	0.57	0.16	0.21	-0.17	0.09	0.28	-0.27	0.4	0.22	0.56	-0.2	0.58
Non Current Assets Total	0.47	0.74	0.65	0.46	0.83	0.46	0.95	0.09	-0.72	0.62	-0.06		-0.23	-0.25	0.44	0.33	0.57	-0.71	0.65	0.61	-0.22	0.48	0.79	0.46	-0.36	0.42
Non Currrent Assets Other	-0.86	-0.51	-0.43	-0.86	-0.58	-0.81	-0.51	0.59	0.7	-0.5	-0.59	-0.23		1.0	-0.86	-0.55	-0.78	0.78	-0.66	-0.79	0.68	-0.83	-0.7	-0.86	0.64	-0.85
Other Assets	-0.87	-0.54	-0.44	-0.87	-0.61	-0.84	-0.52	0.56	0.75	-0.54	-0.56	-0.25	1.0		-0.86	-0.6	-0.82	0.79	-0.69	-0.83	0.67	-0.85	-0.71	-0.87	0.66	-0.86
Cash And Short Term Investments	1.0	0.53	0.33	1.0	0.73	0.9	0.67	-0.58	-0.8	0.71	0.57	0.44	-0.86	-0.86		0.75	0.86	-0.73	0.68	0.89	-0.75	0.93	0.87	1.0	-0.8	1.0
Common Stock Shares Outstanding	0.76	0.65	0.41	0.75	0.69	0.74	0.47	-0.17	-0.79	0.77	0.16	0.33	-0.55	-0.6	0.75		0.77	-0.58	0.75	0.76	-0.37	0.71	0.67	0.76	-0.6	0.75
Short Term Investments	0.86	0.65	0.41	0.86	0.81	0.98	0.72	-0.24	-0.96	0.87	0.21	0.57	-0.78	-0.82	0.86	0.77		-0.81	0.73	1.0	-0.75	0.97	0.89	0.86	-0.88	0.85
Non Current Liabilities Total	-0.76	-0.89	-0.81	-0.75	-0.92	-0.73	-0.86	0.13	0.9	-0.73	-0.17	-0.71	0.78	0.79	-0.73	-0.58	-0.81		-0.93	-0.83	0.47	-0.73	-0.89	-0.76	0.52	-0.72
Other Current Assets	0.71	0.97	0.88	0.7	0.92	0.63	0.78	-0.03	-0.87	0.73	0.09	0.65	-0.66	-0.69	0.68	0.75	0.73	-0.93		0.75	-0.25	0.61	0.82	0.71	-0.38	0.66
Other Stockholder Equity	0.89	0.66	0.44	0.89	0.82	0.98	0.76	-0.3	-0.96	0.85	0.28	0.61	-0.79	-0.83	0.89	0.76	1.0	-0.83	0.75		-0.74	0.97	0.91	0.89	-0.87	0.88
Total Liab	-0.72	-0.1	0.14	-0.74	-0.44	-0.82	-0.4	0.34	0.55	-0.65	-0.27	-0.22	0.68	0.67	-0.75	-0.37	-0.75	0.47	-0.25	-0.74		-0.85	-0.65	-0.72	0.94	-0.75
Net Invested Capital	0.92	0.49	0.26	0.93	0.71	0.99	0.66	-0.44	-0.87	0.78	0.4	0.48	-0.83	-0.85	0.93	0.71	0.97	-0.73	0.61	0.97	-0.85		0.86	0.92	-0.93	0.93
Property Plant And Equipment Gross	0.88	0.76	0.57	0.88	0.95	0.84	0.92	-0.21	-0.92	0.86	0.22	0.79	-0.7	-0.71	0.87	0.67	0.89	-0.89	0.82	0.91	-0.65	0.86		0.88	-0.74	0.86
Total Current Assets	1.0	0.57	0.38	1.0	0.75	0.9	0.69	-0.57	-0.81	0.71	0.56	0.46	-0.86	-0.87	1.0	0.76	0.86	-0.76	0.71	0.89	-0.72	0.92	0.88		-0.78	1.0
Capital Stock	-0.78	-0.25	0.04	-0.79	-0.56	-0.92	-0.5	0.27	0.72	-0.8	-0.2	-0.36	0.64	0.66	-0.8	-0.6	-0.88	0.52	-0.38	-0.87	0.94	-0.93	-0.74	-0.78		-0.8
Net Working Capital	1.0	0.51	0.3	1.0	0.71	0.9	0.65	-0.59	-0.79	0.7	0.58	0.42	-0.85	-0.86	1.0	0.75	0.85	-0.72	0.66	0.88	-0.75	0.93	0.86	1.0	-0.8

Click cells to compare fundamentals

Terns Pharmaceuticals Account Relationship Matchups

Terns Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	23.9M	92.3M	168.1M	287.0M	268.5M	170.3M
Other Current Liab	3.3M	7.5M	3.9M	4.4M	7.0M	5.1M
Total Current Liabilities	5.0M	22.8M	6.8M	8.5M	11.9M	10.5M
Total Stockholder Equity	4.2M	68.6M	160.3M	276.9M	255.4M	153.6M
Other Liab	630K	877K	947K	1.1M	1.2M	806.7K
Net Tangible Assets	(90.8M)	(117.4M)	172.2M	276.9M	318.5M	334.4M
Property Plant And Equipment Net	961K	1.2M	1.0M	1.8M	1.0M	1.2M
Net Debt	(12.3M)	(62.0M)	(47.7M)	(142.0M)	(79.3M)	(83.3M)
Retained Earnings	(91.9M)	(131.9M)	(182.1M)	(242.4M)	(332.6M)	(316.0M)
Accounts Payable	1.6M	935K	2.1M	1.6M	2.5M	1.8M
Cash	12.3M	74.9M	47.7M	143.2M	79.9M	80.8M
Non Current Assets Total	1.7M	1.4M	1.1M	1.8M	1.1M	1.4M
Non Currrent Assets Other	719K	246K	94K	37K	56K	53.2K
Other Assets	719K	246K	94K	37K	1.0	0.95
Cash And Short Term Investments	19.7M	74.9M	166.0M	283.1M	263.4M	163.9M
Common Stock Shares Outstanding	25.1M	25.1M	25.3M	36.0M	71.3M	37.9M
Short Term Investments	7.3M	0.0	118.3M	139.9M	183.5M	192.7M
Liabilities And Stockholders Equity	23.9M	92.3M	168.1M	287.0M	268.5M	170.3M
Non Current Liabilities Total	14.7M	877K	947K	1.6M	1.2M	1.1M
Other Current Assets	461K	3.3M	1.9M	2.1M	4.0M	2.2M
Other Stockholder Equity	1.2M	14.6M	342.7M	520.2M	588.0M	617.4M
Total Liab	19.7M	23.7M	7.8M	10.1M	13.2M	12.2M
Net Invested Capital	(90.8M)	(104.6M)	160.3M	276.9M	255.4M	268.1M
Property Plant And Equipment Gross	961K	1.2M	2.2M	3.2M	2.6M	1.9M
Total Current Assets	22.2M	90.9M	166.9M	285.2M	267.4M	168.9M
Accumulated Other Comprehensive Income	(106K)	(124K)	(338K)	(822K)	(19K)	(20.0K)
Net Working Capital	17.3M	68.0M	160.1M	276.7M	255.5M	158.4M
Property Plant Equipment	961K	1.2M	1.0M	757K	870.6K	924K

Pair Trading with Terns Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Terns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Terns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Terns Stock

0.72

23Andme Holding

Pair Corr

Moving against Terns Stock

0.65	DRUG	Bright Minds Biosciences	Pair Corr
0.51	SABSW	SAB Biotherapeutics	Pair Corr
0.37	KTTAW	Pasithea Therapeutics	Pair Corr
0.35	VERA	Vera Therapeutics	Pair Corr
0.35	DVAX	Dynavax Technologies	Pair Corr

The ability to find closely correlated positions to Terns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Terns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Terns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Terns Pharmaceuticals to buy it.

The correlation of Terns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Terns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Terns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Terns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Terns Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Terns Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Terns Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Terns Pharmaceuticals Stock:

How To Invest In Terns

Details

Is Terns Stock a good investment?

Details

What is Terns Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.

You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.18)

Revenue Per Share

0.035

Return On Assets

(0.19)

Return On Equity

(0.28)

The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Terns Historical Balance Sheet

About Terns Balance Sheet Analysis

Terns Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Terns Pharmaceuticals balance sheet Correlations

Terns Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Terns Pharmaceuticals balance sheet Accounts

Pair Trading with Terns Pharmaceuticals

Moving together with Terns Stock

Moving against Terns Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity

Cash	- 0.99	Net Debt
Other Stockholder Equity	- 0.96	Retained Earnings
Short Term Investments	- 0.96	Retained Earnings
Capital Stock	- 0.93	Net Invested Capital
Other Current Assets	- 0.93	Non Current Liabilities Total
Property Plant And Equipment Gross	- 0.92	Retained Earnings